NCT04639115 2022-06-14A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of OzanimodCelgenePhase 1 Completed26 enrolled